Nuveen Asset Management LLC Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)


Share on StockTwits

Nuveen Asset Management LLC increased its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 9.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,899 shares of the company’s stock after purchasing an additional 12,807 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.32% of Kodiak Sciences worth $20,847,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its holdings in Kodiak Sciences by 25.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,176,211 shares of the company’s stock worth $907,347,000 after purchasing an additional 1,266,263 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Kodiak Sciences in the fourth quarter worth $49,532,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Kodiak Sciences by 18.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 209,110 shares of the company’s stock worth $30,721,000 after buying an additional 33,111 shares in the last quarter. Hillhouse Capital Advisors LTD. bought a new position in shares of Kodiak Sciences during the fourth quarter worth $170,035,000. Finally, American International Group Inc. grew its stake in Kodiak Sciences by 8.6% during the fourth quarter. American International Group Inc. now owns 18,731 shares of the company’s stock valued at $2,752,000 after acquiring an additional 1,478 shares in the last quarter. 82.29% of the stock is currently owned by institutional investors.

Several research analysts have commented on KOD shares. Roth Capital downgraded shares of Kodiak Sciences from a “buy” rating to a “neutral” rating and increased their price objective for the company from $133.00 to $155.00 in a report on Wednesday, February 17th. Morgan Stanley raised their price target on Kodiak Sciences from $125.00 to $133.00 and gave the company an “equal weight” rating in a report on Monday, March 15th. Evercore ISI started coverage on Kodiak Sciences in a report on Wednesday, March 17th. They set an “outperform” rating on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell began coverage on shares of Kodiak Sciences in a research report on Friday, December 11th. They issued a “neutral” rating and a $134.00 price target on the stock. Finally, BMO Capital Markets dropped their price objective on shares of Kodiak Sciences from $148.00 to $138.00 and set a “market perform” rating for the company in a research note on Tuesday, March 2nd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $131.83.

In other news, insider Jason Ehrlich sold 6,950 shares of Kodiak Sciences stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $131.50, for a total transaction of $913,925.00. Following the completion of the sale, the insider now directly owns 69,793 shares in the company, valued at $9,177,779.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 39.30% of the company’s stock.

Shares of NASDAQ KOD opened at $107.46 on Thursday. Kodiak Sciences Inc. has a 1 year low of $42.02 and a 1 year high of $171.21. The firm has a 50-day simple moving average of $123.42 and a two-hundred day simple moving average of $135.18. The company has a market cap of $5.50 billion, a P/E ratio of -46.32 and a beta of 1.42.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Sunday, February 28th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.17). As a group, research analysts predict that Kodiak Sciences Inc. will post -2.8 earnings per share for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Featured Article: Penny Stocks

Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD).

Institutional Ownership by Quarter for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.